Type 2 Diabetes Annual Evaluation Checklist

Why a Structured Annual Visit Matters

A dedicated annual review is not just paperwork. Data from the ACCORD trial (N=10,251) showed that adults with type 2 diabetes who received intensive multifactorial risk-factor management had meaningfully different cardiovascular outcomes than those receiving standard care, underscoring that the full risk profile matters beyond glucose alone. [1] The ADA Standards of Medical Care in Diabetes 2024 state explicitly: "Diabetes management requires a multifactorial approach beyond glycemic control, addressing cardiovascular risk factors, renal function, and preventive care at defined intervals." [2]

The Cost of Missed Checks

Skipping even one domain creates compounding risk. Undetected microalbuminuria can progress to overt nephropathy within three to five years without intervention. [3] Unscreened proliferative retinopathy can cause irreversible vision loss before symptoms appear. The annual visit is the single best clinical opportunity to catch these before they become irreversible.

Who This Checklist Applies To

This checklist applies to any adult with confirmed type 2 diabetes, defined as HbA1c ≥6.5% or fasting plasma glucose ≥126 mg/dL on two separate occasions per the ADA 2024 diagnostic criteria. [2] Patients with gestational diabetes or type 1 diabetes follow modified protocols not covered here.

Checklist Item 1: Glycemic Control Review

Measure HbA1c at every visit if the patient is not at goal, or at minimum twice yearly when stable. For most non-pregnant adults, the ADA target is HbA1c <7.0%. [2] Less stringent targets (HbA1c <8.0%) are appropriate for patients with limited life expectancy, hypoglycemia unawareness, or extensive comorbidities.

What to Measure

• HbA1c (every 3 months if above goal; every 6 months if stable at goal)
• Fasting plasma glucose and postprandial glucose logs or continuous glucose monitoring (CGM) data
• Time-in-range (TIR) if the patient uses CGM: target ≥70% of readings between 70 and 180 mg/dL [2]

Medication Reconciliation

Review all diabetes medications for dose adequacy, side-effect burden, and adherence barriers. The UKPDS 34 trial (N=1,704) demonstrated that metformin reduced all-cause mortality by 36% versus diet alone in overweight patients (P<0.01), making it the preferred first-line agent in most guidelines. [4] If HbA1c remains above goal despite metformin, the ADA recommends adding a GLP-1 receptor agonist or SGLT-2 inhibitor, particularly when the patient has established cardiovascular disease, heart failure, or chronic kidney disease. [2]

Checklist Item 2: Cardiovascular Risk Assessment

Cardiovascular disease is the leading cause of death in adults with type 2 diabetes. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% versus placebo in patients with established ASCVD (hazard ratio 0.62; 95% CI 0.49 to 0.77). [5] Annual assessment must include blood pressure measurement, a fasting lipid panel, and ASCVD 10-year risk calculation.

Blood Pressure

Target: systolic <130 mmHg and diastolic <80 mmHg for most adults with diabetes and hypertension. [2] Measure at every visit using a validated cuff. If two readings on two separate days both exceed 130/80 mmHg, initiate or intensify antihypertensive therapy. ACE inhibitors or ARBs are preferred when albuminuria is present.

Lipid Panel

Order a fasting lipid panel annually. In patients with established ASCVD, target LDL-C <70 mg/dL with high-intensity statin therapy. In patients aged 40 to 75 without ASCVD, moderate- to high-intensity statin therapy is recommended regardless of baseline LDL-C. [2] The CARDS trial (N=2,838) demonstrated that atorvastatin 10 mg reduced major cardiovascular events by 37% in patients with type 2 diabetes who had no prior cardiovascular disease (P=0.001). [6]

Smoking Status

Document and address tobacco use at every visit. Smoking doubles the risk of cardiovascular mortality in patients with diabetes. [7] Offer cessation counseling and pharmacotherapy (varenicline or nicotine replacement) when appropriate.

Checklist Item 3: Kidney Function Screening

Diabetic kidney disease affects approximately 40% of adults with type 2 diabetes and is the most common cause of end-stage renal disease in the United States. [3]

Tests to Order Annually

1. Serum creatinine with calculated eGFR using the CKD-EPI 2021 equation
2. Urine albumin-to-creatinine ratio (UACR) on a spot morning sample

A UACR ≥30 mg/g on two of three samples over three to six months confirms albuminuria. Once confirmed, add an ACE inhibitor or ARB if not already prescribed, and consider an SGLT-2 inhibitor. [2]

SGLT-2 Inhibitors and Kidney Protection

The CREDENCE trial (N=4,401) showed canagliflozin reduced the composite kidney endpoint (dialysis, transplant, or doubling of serum creatinine) by 30% versus placebo in patients with type 2 diabetes and CKD stages 2 to 3 (P<0.001). [8] If eGFR falls below 60 mL/min/1.73 m², refer to nephrology.

Checklist Item 4: Retinal Examination

Diabetic retinopathy remains the leading cause of new-onset blindness among working-age adults in the United States. [9] The ADA recommends a comprehensive dilated eye exam at diagnosis and then annually, though patients with no retinopathy and well-controlled glucose may extend screening to every one to two years after discussion with their ophthalmologist.

What the Exam Should Include

• Dilated fundus examination by an ophthalmologist or optometrist
• Evaluation for macular edema, proliferative retinopathy, and cataracts
• Intraocular pressure screening for glaucoma (elevated in diabetes)

The DCCT/EDIC study (which followed type 1 patients but provided foundational evidence later replicated in type 2 cohorts) showed that intensive glycemic control reduced the development of diabetic retinopathy by 76% at three years compared with conventional control. [10] Tight glucose management remains the primary prevention tool even after retinopathy is detected.

Checklist Item 5: Comprehensive Foot Examination

Lower extremity amputations in people with diabetes are preceded by a foot ulcer in approximately 85% of cases. Annual comprehensive foot exams reduce amputation rates by up to 50% in high-risk populations. [11]

Components of the Annual Foot Exam

• Visual inspection: skin integrity, calluses, nail health, interdigital maceration
• Monofilament test (10-g Semmes-Weinstein): loss of protective sensation at any tested site indicates peripheral neuropathy
• Vibration sense testing with a 128-Hz tuning fork
• Palpation of dorsalis pedis and posterior tibial pulses
• Ankle-brachial index (ABI) if peripheral arterial disease is suspected

Classify each patient as low, moderate, or high risk using the International Working Group on the Diabetic Foot (IWGDF) risk stratification. [11] High-risk patients (prior ulcer or amputation, absent protective sensation plus deformity) need reassessment every one to three months, not just once a year.

Patient Education at the Foot Visit

Provide written instructions: inspect feet daily, avoid walking barefoot, wear well-fitted shoes, and report any new wound within 24 hours. Brief structured foot-care education reduces ulceration rates. [11]

Checklist Item 6: Neuropathy Screening

Distal symmetric polyneuropathy affects up to 50% of adults with long-standing type 2 diabetes. [2] Screen annually with the monofilament test (described above) plus a brief symptom review for burning, tingling, or numbness in a stocking-glove distribution.

Autonomic Neuropathy

Ask specifically about orthostatic dizziness, resting tachycardia, early satiety, constipation or diarrhea, and erectile dysfunction. These point to autonomic neuropathy, which carries an independent cardiovascular mortality risk. [2] Refer to a neurologist or autonomic specialist when two or more autonomic symptoms are present.

Checklist Item 7: Weight and Body Composition

Excess adiposity drives insulin resistance and worsens every cardiovascular risk factor. Track BMI and waist circumference at each annual visit.

Weight Loss Targets

The Look AHEAD trial (N=5,145) demonstrated that an average 8.6% weight loss at one year through intensive lifestyle intervention improved HbA1c, blood pressure, HDL-C, and triglycerides compared with diabetes support and education alone. [12] Even a 5% reduction in body weight produces clinically significant improvements in glycemia.

GLP-1 Receptor Agonists for Weight Management in Diabetes

In STEP-2 (N=1,210), semaglutide 2.4 mg weekly produced 9.6% mean weight loss at 68 weeks in adults with type 2 diabetes versus 3.4% for placebo (P<0.001). [13] Discuss GLP-1 receptor agonist therapy at the annual visit for any patient with BMI ≥27 kg/m² and suboptimal glycemic control.

Checklist Item 8: Immunizations

Adults with diabetes face higher complication rates from vaccine-preventable infections. Influenza, for example, carries a three-fold higher hospitalization risk in people with diabetes versus the general adult population. [14]

Annual and Periodic Vaccines to Review

| Vaccine | Recommendation | |---|---| | Influenza | Every year, any formulation | | COVID-19 | Follow current CDC schedule | | Pneumococcal (PCV15 or PCV20) | Once for all adults ≥65; earlier for diabetes | | Hepatitis B | 3-dose series if previously unvaccinated and aged <60 | | Tdap / Td | Tdap once, then Td booster every 10 years | | Zoster (RZV) | Two-dose series for adults ≥50 |

Review vaccination history at every annual visit and document in the chart. [14]

Checklist Item 9: Mental Health and Social Determinants

Diabetes distress is distinct from clinical depression but equally impactful. A 2023 meta-analysis (N=47 studies, 19,567 participants) found that depression was associated with a 1.5- to 2-fold increase in all-cause mortality in adults with type 2 diabetes. [15]

Screening Tools

• PHQ-2 as a first-pass screen at every annual visit
• PHQ-9 if PHQ-2 score is ≥3
• Diabetes Distress Scale (DDS) for diabetes-specific emotional burden

Screen for food insecurity, housing instability, and transportation barriers, because these predict medication non-adherence more strongly than patient motivation alone. [2] Refer to social work or a community health worker when screening is positive.

Checklist Item 10: Dental and Sleep Screening

Oral Health

Periodontitis and type 2 diabetes maintain a bidirectional relationship: each worsens the other. A Cochrane review (16 trials, N=1,125) found that treating periodontitis reduced HbA1c by approximately 0.29% at three to four months. [16] Recommend at least one dental visit per year and document referral in the chart.

Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is present in an estimated 60 to 80% of adults with obesity and type 2 diabetes. [2] Ask about loud snoring, witnessed apneas, and excessive daytime sleepiness. If two or more symptoms are present, order polysomnography or a validated home sleep apnea test. Treating OSA with CPAP improves insulin sensitivity independent of weight change.

Checklist Item 11: Laboratory Panel Summary

Order the following at least once per year for every patient with type 2 diabetes. Some tests are needed more frequently based on clinical status.

| Test | Frequency | Notes | |---|---|---| | HbA1c | Every 3 months (above goal) or every 6 months (at goal) | Core glycemic metric | | Fasting lipid panel | Annually | More often if on dose-titration | | Serum creatinine / eGFR | Annually | Every 6 months if eGFR <60 | | UACR | Annually | Confirm positive result ×2 | | Liver enzymes (AST/ALT) | Annually | Baseline when starting or changing medications | | TSH | Every 1 to 2 years | Thyroid disease co-occurs at elevated rates | | Vitamin B12 | Annually if on metformin >4 years | Metformin depletes B12 | | Complete blood count | As clinically indicated | Baseline for new medications |

The ADA notes that vitamin B12 deficiency from long-term metformin use occurs in 5 to 10% of patients and is correctable with supplementation. [2]

Checklist Item 12: Medication and Complication Risk Reassessment

Use the annual visit to reassess whether the current medication regimen aligns with the patient's evolving risk profile. The ADA and AACE 2022 consensus statement recommends prioritizing GLP-1 receptor agonists or SGLT-2 inhibitors in patients with established ASCVD, heart failure with reduced ejection fraction, or CKD, regardless of HbA1c level. [17]

Hypoglycemia Risk Review

Document any hypoglycemic episodes since the last visit. Sulfonylureas and insulin carry the highest hypoglycemia burden. Recurrent severe hypoglycemia (requiring third-party assistance) is associated with a 1.79-fold increase in dementia risk over six years. [18] If a patient reports more than two severe episodes per year, reassess the regimen.

Aspirin Therapy

Low-dose aspirin (75 to 100 mg daily) is recommended for secondary prevention in adults with diabetes and established ASCVD. For primary prevention, the benefit-risk ratio is narrower; discuss individually for patients aged 50 to 70 with at least one additional major ASCVD risk factor. [2]

Putting the Checklist Together: A Visit-Day Protocol

A practical approach groups annual tasks into three time blocks during a single 40- to 60-minute visit.

Before the appointment (patient prep, 1 to 2 weeks prior): Order the full laboratory panel (HbA1c, lipids, eGFR, UACR, B12 if indicated, TSH) so results are available at the visit. Have the patient complete the PHQ-2 and the Diabetes Distress Scale in the patient portal.

At the visit (30 to 40 minutes): Review labs with the patient. Perform blood pressure measurement (two readings, two minutes apart), foot exam, monofilament test, weight, and BMI. Update vaccination record and complete medication reconciliation.

After the visit (same day): Generate referrals for ophthalmology (if due), podiatry (if high-risk foot), nephrology (if eGFR <60), dentist, and dietitian. Schedule next HbA1c check based on current control status.

This three-block structure ensures nothing is omitted even in a busy clinic. The ADA recommends using a structured checklist or diabetes registry to track completion rates at the practice level, with a target of ≥80% of patients completing each annual task. [2]